In a cohort of 128 human immunodeficiency virus-infected patients, we found that patients' knowledge of antiretroviral dosing was suboptimal at regimen initiation but improved with time. Poor medication knowledge 8 weeks after regimen initiation was associated with lower adherence and with a lower level of literacy in a multivariate model ( ). Be-P p .03 cause knowledge deficits are common after antiretroviral regimen initiation, clinicians should assess patients' understanding of medication dosing soon after regimen initiation or change.
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Adherence to medical therapy is of critical importance for patients with HIV infection. Poor adherence to antiretroviral therapy is associated with increased mortality and development of drug-resistant HIV strains [1, 2] . Unfortunately, most patients treated with HAART do not achieve the high levels of adherence (195% adherence) necessary to optimize their chances of attaining suppression of HIV replication [3] .
Inadequate knowledge of medication dosing is believed to be one factor associated with medication nonadherence; however, this association is poorly characterized. A lack of understanding of one's condition has been associated with poor ad-herence to health-promoting behaviors [4] , and many patients with chronic disease demonstrate deficits in knowledge about medication dosing [5] [6] [7] . We investigated the association of knowledge of medication dosing with adherence among patients taking antiretroviral medication.
Patients and methods. Patients were enrolled in the Adherence and Efficacy Protease Therapy (ADEPT) study, a prospective, observational investigation of medication adherence among HIV-infected patients starting a new HAART regimen. Antiretroviral regimens were provided at the discretion of the patients' HIV care providers. Subjects were intensively evaluated, on a serial basis, for adherence during 4-week periods [8] . For this analysis, patients who attended у2 study visits during the 48-week study were examined. Informed consent, as defined by the guidelines of the US Department of Health and Human Services (Washington, DC) and the institutions of the authors of the present study, was obtained for all subjects.
Clinical data were collected from medical record reviews and patient interviews. In patient interviews, which were 30 minutes in duration, patients were asked questions about literacy [9] , symptoms of depression, satisfaction with care, social support, trust in the health care provider, and belief in the value of therapy, by use of standardized scales [10] .
At study weeks 0, 8, 24, and 48, study nurses asked each patient the names of his or her antiretroviral medications, the number of times per day that each medication was taken, and the number of pills that were required for each dose; all such questions were asked in the patients' primary language (English or Spanish). To patients who did not know the names of their medications, nurses provided a list that included generic and trade names, commonly used abbreviations for the medications, and pictures of the medications. Nurses noted whether patients used a reminder list or other device (e.g., a pillbox) to help answer questions about dosing knowledge.
Patients visited the study nurses every 4 weeks for measurement of medication adherence. At the beginning of each visit, study nurses asked patients about changes in their medication, performed pill counts, and recorded dosing of medications included in the regimen. Medical records and dispensing pharmacies' dosing instructions printed on pill bottles were used as the "gold standard" of medication dosing against which patients' knowledge of their regimen was compared.
Adherence was measured using 3 methods: pill count, selfreported adherence, and use of Medication Event Monitoring System (MEMS) electronic bottle caps, which register each time the patient opens the pill bottles to which the caps are attached.
MEMS caps were placed either on the pill bottle(s) that contained the patient's protease inhibitor(s) or on the bottle that contained the most frequently dosed antiretroviral medication in regimens that did not include a protease inhibitor. Data from MEMS were retrieved and pill counts were performed every 4 weeks. Medication adherence was computed as the number of doses taken per day divided by the number of doses prescribed during a 4-week period. Self-reporting of adherence, which was done at weeks 8, 24, and 48, required that the patient specify the number of doses missed during the week before the patient interview. Data on adherence, as determined by these 3 measures, were combined into a composite adherence score, described in detail elsewhere [8] , which correlates better with plasma measurements of HIV RNA than does MEMS, pill count, or self-reported adherence measures.
Three domains of knowledge of the antiretroviral regimen were assessed: whether the patient provided the correct name (generic name, trade name, or abbreviation) of his or her antiretroviral medication (known as "med name"), whether the patient knew the correct number of pills per dose (known as "pills/dose"), and whether the patient followed the correct dosing (known as "doses/day") for each medication. If the patient provided correct names for all medications but one, and if the patient provided correct responses for doses/day and pills/dose for the incorrectly named medication, then responses to questions regarding pills/dose and doses/day were considered to be correct but the response to med name was considered to be incorrect. If у2 medications were named incorrectly, then the responses to pills/dose and doses/day were also considered to be incorrect. Scores for each domain were expressed as the number of correct responses divided by the number of medications in the regimen. A summary score of medication knowledge (known as the "medication knowledge score," or MKS) was calculated as the mean of the 3 primary scores. The internal consistency reliability of the MKS was determined. On the basis of literature on prior adherence and clinical judgment, we explored the association of the following factors with medication knowledge: patient age, sex, income, education, social support, language and literacy, regimen characteristics (number of antiretrovirals in the regimen and number of pills per day), duration of previous antiretroviral therapy, severity of HIV disease, depression, perceived value of antiretroviral medication, satisfaction with care, trust in the health care provider, substance abuse, and use of a device (e.g., a pill bottle or a list of medications) to answer dosing questions.
We compared the MKS at each medication knowledge survey with adherence before and after the given survey. A repeatedmeasures multivariate model that was based on the generalized estimating equation was used to predict the MKS at study weeks 0, 8, 24, and 48, incorporating independent variables with a P value of р.20 in bivariate analyses.
Results. Of 140 patients enrolled in the ADEPT study [8] , 128 patients participated in у2 study visits. For these subjects, the mean number of weeks of measured adherence was 32 weeks. The mean age of the subjects was 37 years; 46.9% were Hispanic and 26.9% were African American. The subjects were largely poor, and 53.9% were protease inhibitor naive at the time of entry into the study; the remainder were starting a new regimen. The mean CD4 cell count nadir (‫ע‬SD) was 151 cells/ mL ‫ע‬ 172, and the mean virus load was 5.0 log 10 HIV RNA copies/mL. At baseline, patients were taking a mean of 3.2 antiretroviral medications and 14.3 pills per day (table 1) .
At week 0, on average, patients correctly responded to 80% of questions about med names, 72% of questions about pills/ dose, and 74% of questions about doses/day. Mean scores for all knowledge domains increased significantly by week 8 (P !
Mean patient adherence to medication was 71% for the study period (weeks 0-48). The MKS at week 8 was associated with adherence during the prior study period (weeks 0-8; ), P p .05 as well as with adherence during the subsequent study period (weeks 8-48; ). Every 0.10 increase in the MKS was P p .05 associated with a 2.3% increase in adherence for weeks 0-8 and, also, with a 1.9% increase for weeks 8-48. There was no significant correlation between the MKS and adherence at weeks 0, 24, and 48.
Because the relationship between the MKS and adherence was strongest at week 8, we investigated postulated predictors of the MKS at this point in time. Bivariate predictors of low MKS at week 8 were income !$10,000 ( ), failure to P p .05 complete high school ( ), no participation in a clinical P p .001 trial ( ), and lower level of literacy ( ) (table 1) . P p .01 P p .005 In the repeated-measures multivariate model predicting MKS that included income, education, literacy, age, clinical trial participation, language, social support, use of a device to complete the knowledge survey, and number of pills as predictors, independent predictors were a lower level of literacy ( ) P p .03 and use of a device to complete the survey ( ). For each P p .01 1-point increase in the 36-point literacy score, the MKS increased by 0.5%; use of a device to complete the survey increased the MKS by 7%.
Discussion. The present study quantified the association of knowledge of medication dosing with medication adherence. Poor knowledge of antiretroviral dosing was common soon after a new regimen was prescribed. By week 8 of the study, three-fourths of patients perfectly recalled the medication dos- ing. Nevertheless, among this subgroup, adherence was suboptimal after this point in time (mean adherence, !85%), a finding that demonstrates that proper understanding of dosing instructions is essential, but insufficient, for medication adherence. In addition, some patients had persistent deficits in dosing knowledge. Early inability to describe one's medication dosing was associated with early nonadherence. Our findings suggest that a low level of education, a low level of literacy, a low income, and nonparticipation in a clinical trial are associated with lower comprehension of medication dosing. Of interest, patient attitudes and beliefs (factors usually more strongly associated with medication adherence [11] ) were not associated with dosing knowledge. Clinical factors and regimen-associated factors also were unassociated with dosing knowledge. Prescribing a more complex antiretroviral regimen may not be a significant barrier to understanding medication dosing. The association of dosing knowledge with clinical trial participation suggests that patients may benefit from the attention received in this setting or may reflect selection bias in trial enrollment. Finally, it is not surprising that use of an assistive device leads to higher knowledge scores.
Querying patients about dosing immediately after they start taking medications may have limited usefulness. The association of knowledge with adherence 8 weeks after initiation of a regimen suggests that medication knowledge should be assessed soon after a change in the regimen. The lack of association of knowledge with late adherence probably is the result of high knowledge scores with low variance. These findings are consistent with those of other investigations that demonstrate knowledge deficits concerning disease-related information; however, prior studies either did not measure the association of adherence or used subjective reports [6, 8, 12, 13] .
This study has several limitations. First, 9% of the cohort did not complete 11 knowledge survey and could not be analyzed; however, increases in the MKS after week 0 were not the result of attrition. Second, we measured medication knowledge through patient recall. Patients who rely on pillboxes and other devices may be able to have medication adherence without having full knowledge of their regimen. Third, sample size may have limited our ability to detect factors related to knowledge.
To our knowledge, this is the first investigation of factors associated with medication knowledge. For patients receiving HAART, deficits in knowledge about the dosing instructions for their medications are common and are associated with lower medication adherence. The association of poor dosing knowledge with adherence demands that patient understanding of medication dosing be confirmed soon after a change in the regimen. Because a lower level of literacy is an independent predictor of deficits in medication knowledge, asking a patient to verbally describe his or her medications and dosing may the most effective way to assess medication knowledge. Specific interventions should target patients with low levels of education and literacy to help them learn dosing instructions.
